Articles tagged "Kidney transplantation"

2020 American Transplant Congress
Caspase-1 Knockout Mice Have Increased Survival after Cold Ischemia in a Murine Kidney Transplant Model
S. Jain¹, R. Plenter², T. Nydam², A. Jani¹
¹Renal, University of Colorado, Aurora, CO, ²Transplant Microsurgery Program, University of Colorado, Aurora, CO
*Purpose: Prolonged cold ischemia (CI) is a known risk factor for acute kidney injury (AKI) after kidney transplantation. However, the mechanism by which CI leads…
2020 American Transplant Congress
A Novel Polymer Product, APP-103, Reduces IRI-Induced Damage and Promotes Functional Improvement in Syngeneic Models of Renal Transplantation
K. Minami¹, S. Bae², H. Uehara¹, J. Iske¹, J. Reder³, H. Azuma⁴, A. Weins¹, E. Van Keuren⁵, B. Houser³, A. El-Khal¹, P. Kang², S. Tullius¹
¹Brigham and Women's Hospital, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Celdara Medical, Lebanon, NH, ⁴Osaka Medical College, Osaka, Japan, ⁵Georgetown University, Washington DC, DC
*Purpose: Our data introduce APP-103 as a novel, non-toxic and site-activating therapeutic approach that effectively ameliorates the consequences of ischemia/reperfusion injury in solid organ transplantation.*Methods:…
2020 American Transplant Congress
Patient-Reported Outcomes in a Prospective Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression Regimens in Kidney Transplantation: A Prospective Analysis Across Two Years
J. M. Rohan¹, J. Leone², E. Woodle³, D. Kaufman⁴, A. Shields⁵, A. Wiseman⁶, A. Matas⁷, P. West-Thielke⁸, E. King⁵, R. Alloway³
¹Pediatrics, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA, ²Tampa General, Tampa, FL, ³University of Cincinnati, Cincinnati, OH, ⁴U Wisconsin, Madison, WI, ⁵U Cincinnati, Cincinnati, OH, ⁶U Colorado, Denver, CO, ⁷U Minnesota, Minneapolis, MN, ⁸UIC, Chicago, IL
*Purpose: Previous trials have not examined 2-year longitudinal differences in patient-reported outcomes (PRO) between belatacept (BELA)- and tacrolimus (TAC)-based therapies in adult kidney transplant (KTx)…
2020 American Transplant Congress
Wage Reimbursement by the NKR: A Critical Step Towards Financial Neutrality for Living Kidney Donors
N. Garg¹, T. D’Alessandro², M. Ronin², A. D. Waterman³, M. Cooper⁴, G. Hil², D. A. Mandelbrot¹
¹UW-Madison, Madison, WI, ²NKR, Babylon, NY, ³UCLA, Terasaki Research Institute, Los Angeles, CA, ⁴Georgetown University, Washington, DC
*Purpose: The potential for out-of-pocket expenses incurred by living kidney donors has been identified as an important barrier to proceeding with live donation, with financial…
2020 American Transplant Congress
A Single Centre Report of Renal Transplantation Against a Positive Crossmatch Due to HLA-DP Donor Specific Antibodies without Prior Antibody Removal
Y. Marie¹, T. Key², A. Halawa¹
¹Renal Transplantation, Sheffield Kidney Institute, Sheffield, United Kingdom, ²2.Department of Histocompatibility and Immunogenetics, Sheffield, United Kingdom
*Purpose: In renal transplantation, the clinical effects of donor specific antibodies (DSA) against HLA-DP are unclear. We report successful kidney transplants in three highly sensitised…
2020 American Transplant Congress
Post-Operative Opiate Utilization and Prescribing Patterns in Living Kidney Donors
E. Calderon¹, D. S. Ubl², C. Jadlowiec¹, P. Dean³, E. Castle⁴, P. Andrews⁴, B. Taner⁵, E. Habermann², A. K. Mathur¹
¹Transplant Surgery, Mayo Clinic, Phoenix, AZ, ²Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, ³Transplant Surgery, Mayo Clinic, Rochester, MN, ⁴Department of Urology, Mayo Clinic, Phoenix, AZ, ⁵Transplant Surgery, Mayo Clinic, Jacksonville, FL
*Purpose: Living kidney donors (LKDs) become exposed to opioids during routine post-surgical care, which may lead to adverse outcomes. and since there is an absence…
2020 American Transplant Congress
Factors Associated with Renal Graft Loss in Simultaneous Kidney-Heart Transplant Recipients in the UNOS Cohort
K. A. Agarwal¹, H. Patel¹, K. Almonte², F. Cardarelli¹, N. Agrawal¹
¹Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Mount Auburn Hospital, Cambridge, MA
*Purpose: Simultaneous kidney and heart transplants (SKHT) are employed for patients with both end-stage heart failure and severely impaired kidney function. Renal outcomes in such…
2020 American Transplant Congress
Virtual XM Adversely Affects Access for Highly Sensitized African Americans Awaiting Renal Transplantation
P. T. Jindra¹, B. V. Murthy¹, C. Van Buren²
¹Surgery, Baylor College of Medicine, Houston, TX, ²Surgery, UT Medical School, Houston, TX
*Purpose: Recent UNOS policy proposals have changed kidney allocation from local Designated Service Areas (DSA) to geographic distribution areas of varying widths. Since crossmatch of…
2020 American Transplant Congress
Improved Outcomes Over the Past 13 Years in HIV Positive Kidney Transplant Recipients-A Single Center Experience
A. Mattiazzi¹, J. F. Camargo², S. Anjan², M. I. Morris², L. Abbo², J. Simkins², Y. Natori², K. Aoke³, A. Zilli³, R. Thurston³, M. Muldoon³, L. Preczewski³, L. J. Chen⁴, G. W. Burke⁴, G. Ciancio⁴, G. Guerra¹
¹Medicine. Division of Nephrology, University of Miami/Miami Transplant Institute, Miami, FL, ²Medine. Division of Infectious Disease, University of Miami/Miami Transplant Institute, Miami, FL, ³Miami Transplant Institute, Miami, FL, ⁴Surgery, University of Miami/Miami Transplant Institute, Miami, FL
*Purpose: Kidney transplantation in HIV positive recipients (HIV+) is the treatment of choice for renal failure in patients (P) who maintain CD4+ counts ≥ 200/mm3and…
2020 American Transplant Congress
Impact of Extended- versus Immediate-Release Tacrolimus on One-Year Development of De Novo DSA and Chronic Immune Activation in Kidney Transplantation (ASTOUND Study)
A. Wiseman¹, D. Kaufman², A. Patel³, D. Wojciechowski⁴, A. Tambur⁵, J. Kim⁶, J. Schwartz⁶
¹University of Colorado Hospital, Aurora, CO, ²University of Wisconsin, Madison, WI, ³Henry Ford Hospital, Detroit, MS, ⁴Massachusetts General Hospital, Boston, MA, ⁵Northwestern University, Chicago, IL, ⁶Astellas Pharma Global Development, Northbrook, IL
*Purpose: To compare, using an adaptive study design, the 1-year incidence of a novel two-part composite endpoint consisting of de novo donor-specific antibody (dnDSA) formation…